Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics

摘要 请求支持题为现代表型药物发现的Keystone研讨会： 化学生物学到治疗学，由布里奇特·瓦格纳博士、尼尔·卡拉格博士、杰里米·詹金斯博士和 劳拉·基斯林。大会将于2022年5月22日至25日在科罗拉多州丹佛市举行。 表型药物发现(PDD)作为药物发现和化学生物学的一种方法已经建立起来 学术界和工业界的势头和兴奋。新技术平台的融合 (例如，诱导多能干细胞、CRISPR-Cas9基因编辑、3D生物学、先进成像)与其他 化学信息学、机器学习和人工智能等学科带来了令人兴奋的 PDD的复兴。这次会议将汇集对表型感兴趣或正在进行研究的研究人员。 来自学术界和工业界的药物发现。尽管PDD的现代进展跨越了两个学术领域 和行业部门，很少有以药物发现为重点的非商业性会议可供 社区，而Keystone研讨会计划是这个主题的主要论坛。这次会议的目的是 分享新的PDD技术、生物模型和人类疾病领域的信息和最佳实践， 以及促进学术界和产业界的协作讨论。另外，这次会议， 该计划将解决该领域的几个关键障碍：如何提高 表型模型和识别表型靶标以及了解化合物的作用机制 (MOA)。预计与会者将带着对表型策略的重新认识离开 化学生物学领域的广泛领域，并将通过扩大我们的集体努力来推动该领域的发展 推动改进的化验模型和尖端的MOA技术的边界。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics, organized by Drs. Bridget Wagner, Neil Carragher, Jeremy Jenkins and Laura Kiessling. The conference will be held in Denver, Colorado from May 22-25, 2022. Phenotypic Drug Discovery (PDD) as an approach to drug discovery and chemical biology has been building momentum and excitement in both academia and industry. The convergence of new technology platforms (e.g., induced pluripotent stem cells, CRISPR-Cas9 gene editing, 3D biology, advanced imaging) with other disciplines such as cheminformatics, machine learning, and artificial intelligence have led to an exciting renaissance of PDD. This conference will bring together researchers performing or interested in phenotypic drug discovery from across academia and industry. Although modern advances in PDD span both academic and industry sectors, there are few non-commercial drug discovery-focused meetings available for the community, and the Keystone Symposia program is a premiere forum for this topic. This conference aims to share information and best practices in new PDD technologies, biological models, and human disease areas, as well as foster collaborative discussions across academia and industry. Additionally, this conference program will address several critical barriers in the field: how to improve the physiological relevance of phenotypic models and identifying a phenotypic target and understanding a compound’s mechanism of action (MoA). It is anticipated that attendees will leave with a renewed appreciation for phenotypic strategies in a wide variety of areas in chemical biology, and that the field will be advanced by expanding our collective efforts to push the boundaries of improved assay models and cutting-edge MoA technologies.